Cited by 393Gout, Hyperuricemia, Uric AcidHeart Failure Treatment and ManagementCardiovascular Function and Risk Factors

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Impact of Oxypurinol in Patients With Symptomatic Heart Failure

Open access

Hare, Joshua M., Mangal, Brian, Brown, Joanne, Fisher, Charles, Freudenberger, Ronald, Colucci, Wilson S., Mann, Douglas L., Liu, Peter, Givertz, Michael M., Schwarz, Richard P.·2008·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2008.01.068

Open this paper in CoChat — free account

Abstract

Objectives This study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical therapy.Background Increased XO activity may contribute to heart failure pathophysiology.Methods Patients (n = 405) were randomized to oxypurinol (600 mg/day) or placebo. Efficacy at 24 weeks was assessed using a composite end point comprising heart failure morbidity, mortality, and quality of life.Results The percentage of patients characterized as improved, unchanged, or worsened did not differ between those receiving oxypurinol or placebo. Oxypurinol reduced serum uric acid (SUA) by approximately 2 mg/dl (p < 0.001). In a subgroup analysis, patients with elevated SUA (>9.5 mg/dl, n = 108) responded favorably to oxypurinol (p = 0.02 for interaction term), whereas oxypurinol patients with SUA <9.5 mg/dl exhibited a trend towards worsening. In addition, SUA reduction to oxypurinol correlated with favorable clinical response. Within the entire oxypurinol patient cohort, those characterized as either improved or unchanged had significantly greater reductions in SUA compared with patients who worsened (-2.3 +/- 2.1 mg/dl vs. -1.0 +/- 1.9 mg/dl, p = 0.0006). In placebo patients, lower baseline SUA, but not change in SUA, correlated with improved clinical outcome.Conclusions Oxypurinol did not produce clinical improvements in unselected patients with moderate-to-severe heart failure. However, post-hoc analysis suggests that benefits occur in patients with elevated SUA in a manner correlating with the degree of SUA reduction. Serum uric acid may serve as a valuable biomarker to target XO inhibition in heart failure. (Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure; NCT00063687).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2008.01.068

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications
Berry, C. E., & Hare, J. M. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.055913 · Cited by 925
Self-citation
Uric Acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging
Anker, S. D., Doehner, W., Rauchhaus, M., Sharma, R., Francis, D., Knosalla, C., Davos, C. H., Cicoira, M., Shamim, W., Kemp, M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000065637.10517.a0 · Cited by 593
High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid
Casella, G., Carr, E., Davies, J. I., Belch, J. J. F., & Struthers, A. D. (2006) · Circulation · doi:10.1161/circulationaha.106.651117 · Cited by 574
Uric Acid, Hominoid Evolution, and the Pathogenesis of Salt-Sensitivity
Watanabe, S., Kang, D., Feng, L., Nakagawa, T., Kanellis, J., Lan, H. Y., Mazzali, M., & Johnson, R. J. (2002) · Hypertension · doi:10.1161/01.hyp.0000028589.66335.aa · Cited by 562
Vascular Oxidative Stress and Endothelial Dysfunction in Patients With Chronic Heart Failure
Landmesser, U., Spiekermann, S., Dikalov, S., Tatge, H., Wilke, R., Kohler, C., Harrison, D. G., Hornig, B., & Drexler, H. (2002) · Circulation · doi:10.1161/01.cir.0000041431.57222.af · Cited by 525
Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure
Farquharson, C. A. J., Butler, R., Hill, A., Belch, J. J. F., & Struthers, A. D. (2002) · Circulation · doi:10.1161/01.cir.0000022140.61460.1d · Cited by 504
Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy
Cappola, T. P., Kass, D. A., Nelson, G. S., Berger, R. D., Rosas, G. O., Kobeissi, Z. A., Marbán, E., & Hare, J. M. (2001) · Circulation · doi:10.1161/hc4501.098928 · Cited by 436
Self-citation
Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure
Packer, M. (2001) · Journal of Cardiac Failure · doi:10.1054/jcaf.2001.25652 · Cited by 397
Electron Spin Resonance Characterization of Vascular Xanthine and NAD(P)H Oxidase Activity in Patients With Coronary Artery Disease
Spiekermann, S., Landmesser, U., Dikalov, S., Bredt, M., Gamez, G., Tatge, H., Reepschläger, N., Hornig, B., Drexler, H., & Harrison, D. G. (2003) · Circulation · doi:10.1161/01.cir.0000056762.69302.46 · Cited by 298
Angiotensin II Induces Endothelial Xanthine Oxidase Activation: Role for Endothelial Dysfunction in Patients With Coronary Disease
Landmesser, U., Spiekermann, S., Preuss, C., Sorrentino, S., Fischer, D., Manes, C., Mueller, M., & Drexler, H. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000258415.32883.bf · Cited by 210

Flagged first, then by citations

Show all 25 references

Sorted by citations

Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 19,890
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644
2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,340
Treating Oxidative Stress in Heart Failure: Past, Present and Future
van der Pol, A., van Gilst, W. H., Voors, A. A., & van der Meer, P. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1320 · Cited by 838
Reappraising the role of inflammation in heart failure
Adamo, L., Resende, C. R., Prabhu, S. D., & Mann, D. L. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0315-x · Cited by 782
Self-citation
Reactive oxygen species in cardiovascular disease
Sugamura, K., & Keaney (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.05.004 · Cited by 769
Inflammation in Heart Failure
Murphy, S., Kakkar, R. K., McCarthy, C. P., & Januzzi, J. L. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.01.014 · Cited by 791
Innate Immunity and the Failing Heart
Mann, D. L. (2015) · Circulation Research · doi:10.1161/circresaha.116.302317 · Cited by 690
Self-citation
Impact of Oxidative Stress on the Heart and Vasculature
Münzel, T. F., Camici, G. G., Maack, C., Bonetti, N. R., Fuster, V., & Kovacic, J. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.05.035 · Cited by 642
Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation
Tejero, J., Shiva, S., & Gladwin, M. T. (2019) · Physiological Reviews · doi:10.1152/physrev.00036.2017 · Cited by 541
NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets
Zhang, Y., Murugesan, P., Huang, K., & Cai, H. “. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0260-8 · Cited by 551
Oxidative stress and left ventricular remodelling after myocardial infarction
Hori, M., & Nishida, K. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn335 · Cited by 531
Uric acid and cardiovascular disease
Ndrepepa, G. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.05.046 · Cited by 512
Endothelial Dysfunction, Arterial Stiffness, and Heart Failure
Marti, C. N., Gheorghiade, M., Kalogeropoulos, A. P., Georgiopoulou, V. V., Quyyumi, A. A., & Butler, J. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.082 · Cited by 500
Is oxidative stress a therapeutic target in cardiovascular disease?
Münzel, T., Gori, T., Bruno, R. M., & Taddei, S. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq396 · Cited by 470
The role of uric acid in the pathogenesis of human cardiovascular disease
Kanbay, M., Segal, M. S., Afşar, B., Kang, D., Rodríguez‐Iturbe, B., & Johnson, R. J. (2013) · Heart · doi:10.1136/heartjnl-2012-302535 · Cited by 458
Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease
Borghi, C., Agabiti‐Rosei, E., Johnson, R. J., Kielstein, J. T., Lurbe, E., Mancia, G., Redón, J., Stack, A. G., & Tsioufis, K. P. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.07.006 · Cited by 462
National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018
Atherton, J. J., Sindone, A. P., Pasquale, C. G. D., Driscoll, A. L., Macdonald, P. S., Hopper, I., Kistler, P. M., Briffa, T. G., Wong, J., Abhayaratna, W. P., et al. (2018) · Heart Lung and Circulation · doi:10.1016/j.hlc.2018.06.1042 · Cited by 437
Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications
Münzel, T., Gori, T., Keaney, J. F., Maack, C., & Daiber, A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv305 · Cited by 394
The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor
D’Oria, R., Schipani, R., Leonardini, A., Natalicchio, A., Perrini, S., Cignarelli, A., Laviola, L., & Giorgino, F. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5732956 · Cited by 399
Uric acid and cardiovascular disease: A clinical review
Saito, Y., Tanaka, A., Node, K., & Kobayashi, Y. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.12.013 · Cited by 381
Cardiac progenitor cell-derived exosomes prevent cardiomyocytes apoptosis through exosomal miR-21 by targeting PDCD4
Xiao, J., Pan, Y., Li, X. H., Yang, X. Y., Feng, Y. L., Tan, H. H., Jiang, L., Feng, J., & Yu, X. Y. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.181 · Cited by 373
Inflammatory Cytokines in Heart Failure: Mediators and Markers
Gullestad, L. L., Ueland, T., Vinge, L. E., Finsen, A. V., Yndestad, A., & Aukrust, P. (2012) · Cardiology · doi:10.1159/000338166 · Cited by 355
Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies
Aimo, A., Castiglione, V., Borrelli, C., Saccaro, L. F., Franzini, M., Masi, S., Emdin, M., & Giannoni, A. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319870344 · Cited by 362
Inflammation as a Therapeutic Target in Heart Failure? A Scientific Statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology
Heymans, S. R. B., Hirsch, E., Anker, S. D., Aukrust, P., Balligand, J., Tervaert, J. W. C., Drexler, H., Filippatos, G. S., Felix, S. B., Gullestad, L. L., et al. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfn043 · Cited by 325
Oxidized Ca 2+ /Calmodulin-Dependent Protein Kinase II Triggers Atrial Fibrillation
Purohit, A., Rokita, A. G., Guan, X., Chen, B., Koval, O. M., Voigt, N., Neef, S., Sowa, T., Gao, Z., Luczak, E. D., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.003313 · Cited by 319
Biochemical basis and metabolic interplay of redox regulation
Zhang, L., Wang, X., Cueto, R., Effi, C., Zhang, Y., Tan, H., Qin, X., Ji, Y., Yang, X., & Wang, H. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101284 · Cited by 308
Established and Emerging Roles of Biomarkers in Heart Failure
Ibrahim, N. E., & Januzzi, J. L. (2018) · Circulation Research · doi:10.1161/circresaha.118.312706 · Cited by 307
Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study
Givertz, M. M., Anstrom, K. J., Redfield, M. M., Deswal, A., Haddad, H., Butler, J., Tang, W. H. W., Dunlap, M. E., LeWinter, M. M., Mann, D. L., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.014536 · Cited by 296
Self-citation
Cardiac oxidative stress in diabetes: Mechanisms and therapeutic potential
Faria, A., & Persaud, S. J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.013 · Cited by 302
Pathophysiology of circulating xanthine oxidoreductase: New emerging roles for a multi-tasking enzyme
Battelli, M. G., Bolognesi, A., & Polito, L. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.022 · Cited by 256
Metabolic Impairment in Heart Failure
Doehner, W., Frenneaux, M. P., & Anker, S. D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.083 · Cited by 241
The relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: Molecular mechanisms and clinical implications
Puddu, P., Puddu, G. M., Cravero, E., Vizioli, L., & Muscari, A. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.01.013 · Cited by 245
Redox signaling in cardiovascular health and disease
Madamanchi, N. R., & Runge, M. S. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.04.001 · Cited by 228
U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia
Crawley, W. T., Jungels, C., Stenmark, K. R., & Fini, M. A. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102271 · Cited by 230
Cardioprotective microRNAs: Lessons from stem cell-derived exosomal microRNAs to treat cardiovascular disease
Moghaddam, A. S., Afshari, J. T., Esmaeili, S., Saburi, E., Joneidi, Z., & Momtazi‐Borojeni, A. A. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.03.016 · Cited by 204
Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury
Kaludercic, N., Carpi, A., Menabò, R., Lisa, F. D., & Paolocci, N. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.09.010 · Cited by 197
Journal of Pharmaceutical and Biomedical Sciences
(2016) · Journal of Pharmaceutical and Biomedical Sciences · doi:10.20936/jpbms · Cited by 193
Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement
Mensah, G. A., Arnold, N., Prabhu, S. D., Ridker, P. M., & Welty, F. K. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.047 · Cited by 231
Role of endothelial dysfunction in heart failure
Zuchi, C., Tritto, I., Carluccio, E., Mattei, C., Cattadori, G., & Ambrosio, G. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09881-3 · Cited by 205
Uric Acid-Lowering Treatment With Benzbromarone in Patients With Heart Failure
Oginö, K., Kato, M., Furuse, Y., Kinugasa, Y., Ishida, K., Osaki, S., Kinugawa, T., Igawa, O., Hisatome, I., Shigemasa, C., et al. (2009) · Circulation Heart Failure · doi:10.1161/circheartfailure.109.868604 · Cited by 191
Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials
Bredemeier, M., Lopes, L. M., Eisenreich, M. A., Hickmann, S., Bongiorno, G. K., Davila, R., Morsch, A., Stein, F. D. S., & Campos, G. G. D. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0757-9 · Cited by 187
Antioxidants in Cardiovascular Therapy: Panacea or False Hope?
Goszcz, K., Deakin, S. J., Duthie, G. G., Stewart, D., Leslie, S. J., & Megson, I. L. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00029 · Cited by 188
Relation of serum uric acid to cardiovascular disease
Wu, A. H., Gladden, J. D., Ahmed, M. I., Ahmed, A., & Filippatos, G. S. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.110 · Cited by 183
Xanthine oxidoreductase in atherosclerosis pathogenesis: Not only oxidative stress
Battelli, M. G., Polito, L., & Bolognesi, A. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.10.006 · Cited by 179
Oxidative Stress and Hyperuricaemia: Pathophysiology, Clinical Relevance, and Therapeutic Implications in Chronic Heart Failure
Bergamini, C., Cicoira, M., Rossi, A., & Vassanelli, C. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp042 · Cited by 166
Xanthine Oxidase Inhibition For The Treatment Of Cardiovascular Disease: A Systematic Review and Meta‐Analysis
Higgins, P., Dawson, J., Lees, K. R., McArthur, K., Quinn, T. J., & Walters, M. R. (2012) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2011.00277.x · Cited by 164
Nitric Oxide Synthases in Heart Failure
Carnicer, R., Crabtree, M. J., Sivakumaran, V., Casadei, B., & Kass, D. A. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.4824 · Cited by 169
Inflammation in heart failure: pathophysiology and therapeutic strategies
Boulet, J., Sridhar, V. S., Bouabdallaoui, N., Tardif, J., & White, M. (2024) · Inflammation Research · doi:10.1007/s00011-023-01845-6 · Cited by 173
Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets
Reina‐Couto, M., Pereira‐Terra, P., Quelhas‐Santos, J., Silva-Pereira, C., Albino‐Teixeira, A., & Sousa, T. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.746494 · Cited by 164
Uric Acid as a Predictor of All-Cause Mortality in Heart Failure: A Meta-Analysis
Tamariz, L. J., Harzand, A., Palacio, A., Verma, S., Jones, J. L., & Hare, J. M. (2011) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2011.00200.x · Cited by 146
Self-citation
Gout, Allopurinol Use, and Heart Failure Outcomes
Thanassoulis, G. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.198 · Cited by 147
Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data
Filippatos, G. S., Ahmed, M. I., Gladden, J. D., Mujib, M. U., Aban, I., Love, T. E., Sanders, P. W., Pitt, B., Anker, S. D., & Ahmed, A. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq473 · Cited by 146
Uric Acid and Cardiovascular Disease: An Update
Muiesan, M. L., Rosei, C. A., Paini, A., & Salvetti, M. (2016) · European Cardiology Review · doi:10.15420/ecr.2016:4:2 · Cited by 140
Documento de consenso para la detección y manejo de la enfermedad renal crónica
Martínez‐Castelao, A., Górriz, J. L., Bover, J., la Morena, J. S.-D., Cebollada, J., Escalada, J., Esmatjes, E., Fácila, L., Gamarra, J., Gràcia, S., et al. (2014) · Atención Primaria · doi:10.1016/j.aprim.2014.09.002 · Cited by 137
Novel therapeutic targets for the treatment of heart failure
Tamargo, J. L., & Lopez-Sendon, J. L. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3431 · Cited by 133
Association between serum uric acid and atrial fibrillation: A systematic review and meta-analysis
Tamariz, L. J., Hernandez, F., Bush, A. L., Palacio, A., & Hare, J. M. (2014) · Heart Rhythm · doi:10.1016/j.hrthm.2014.04.003 · Cited by 131
Self-citation
Biomarkers in heart failure: the past, current and future
Michael, S., Wang, Y., Wei, J., Huang, Y., Li, M., Li, L., Acheampong, E., Zhou, Z., Xiaoyan, Q., Xu, Y., et al. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09807-z · Cited by 128
Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.027 · Cited by 145
Allopurinol and Cardiovascular Outcomes in Adults With Hypertension
MacIsaac, R. L., Salatzki, J., Higgins, P., Walters, M. R., Padmanabhan, S., Dominiczak, A. F., Touyz, R. M., & Dawson, J. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.06344 · Cited by 124
Remodeling of Calcium Handling in Human Heart Failure
Lou, Q., Janardhan, A. H., & Efimov, I. R. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2888-2_52 · Cited by 123
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease ― Japanese Guideline on the Management of Asymptomatic Hyperuricemia ―
Hisatome, I., Li, P., Miake, J., Taufiq, F., Mahati, E., Maharani, N., Utami, S. B., Kuwabara, M., Bahrudin, U., & Ninomiya, H. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0406 · Cited by 131
Predictors of Clinical Outcomes in Elderly Patients with Heart Failure
Manzano, L., Babalis, D. S., Roughton, M., Shibata, M. C., Anker, S. D., Ghio, S., van Veldhuisen, D. J., Solal, A. C., Coats, A. J. S., Poole-Wilson, P. A., et al. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr030 · Cited by 120
A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout
Chao, J., & Terkeltaub, R. A. (2009) · Current Rheumatology Reports · doi:10.1007/s11926-009-0019-z · Cited by 115
Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
Elrakaybi, A., Laubner, K., Zhou, Q., Hug, M. J., & Seufert, J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101549 · Cited by 117
Xanthine Oxidase and Uric Acid in Cardiovascular Disease: Clinical Impact and Therapeutic Options
Doehner, W., & Landmesser, U. (2011) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2011.08.007 · Cited by 110
Potential novel pharmacological therapies for myocardial remodelling
Landmesser, U., Wollert, K. C., & Drexler, H. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn317 · Cited by 109
How can we cure a heart “in flame”? A translational view on inflammation in heart failure
Hofmann, U., & Frantz, S. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0356-y · Cited by 110
Gout and its comorbidities: implications for therapy
Stamp, L. K., & Chapman, P. T. (2012) · Lara D. Veeken · doi:10.1093/rheumatology/kes211 · Cited by 107
Allopurinol Acutely Increases Adenosine Triphospate Energy Delivery in Failing Human Hearts
Hirsch, G. A., Bottomley, P. A., Gerstenblith, G., & Weiss, R. G. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.10.895 · Cited by 103
Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management
O’Dell, J. R., Brophy, M. T., Pillinger, M. H., Neogi, T., Palevsky, P. M., Wu, H., Davis‐Karim, A., Newcomb, J. A., Ferguson, R. E., Pittman, D., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100028 · Cited by 110
Mitochondrial dysfunction and oxidative stress in CHF
Okonko, D. O., & Shah, A. M. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.189 · Cited by 103
Gout and the risk for incident heart failure and systolic dysfunction
Krishnan, E. (2012) · BMJ Open · doi:10.1136/bmjopen-2011-000282 · Cited by 101
Allopurinol as a therapeutic option in cardiovascular disease
Okafor, O., Farrington, K., & Gorog, D. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.12.004 · Cited by 102
Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials With Allopurinol and SGLT2 Inhibitors
Packer, M. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.08.015 · Cited by 95
Hyperuricemia in Kidney Disease: A Major Risk Factor for Cardiovascular Events, Vascular Calcification, and Renal Damage
Ejaz, A. A., Nakagawa, T., Kanbay, M., Kuwabara, M., Kumar, A., García‐Arroyo, F. E., Roncal-Jiménez, C. A., Sasai, F., Kang, D., Jensen, T., et al. (2020) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2020.12.004 · Cited by 98
Oxidative and nitrosative stress in the maintenance of myocardial function
Zhang, Y., Tocchetti, C. G., Krieg, T., & Moens, A. L. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.07.010 · Cited by 96
S -Nitrosothiols and the S -Nitrosoproteome of the Cardiovascular System
Maron, B. A., Tang, S., & Loscalzo, J. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.4744 · Cited by 101
Oxidative Stress in Heart Failure: What Are We Missing?
Sawyer, D. B. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3182249fcd · Cited by 93
Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease
Sampson, A. L., Singer, R. F., & Walters, G. D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009460.pub2 · Cited by 96
Update in uric acid, hypertension, and cardiovascular diseases
Kuwabara, M., Kodama, T., Ae, R., Kanbay, M., Andrés-Hernando, A., Borghi, C., Hisatome, I., & Lanaspa, M. A. (2023) · Hypertension Research · doi:10.1038/s41440-023-01273-3 · Cited by 92
Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial
Higgins, P., Walters, M. R., Murray, H. M., McArthur, K., McConnachie, A., Lees, K. R., & Dawson, J. (2014) · Heart · doi:10.1136/heartjnl-2014-305683 · Cited by 91
Plasma Xanthine Oxidoreductase Activity as a Novel Biomarker of Metabolic Disorders in a General Population
Furuhashi, M., Matsumoto, M., Tanaka, M., Moniwa, N., Murase, T., Nakamura, T., Ohnishi, H., Saitoh, S., Shimamoto, K., & Miura, T. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0082 · Cited by 90
Uric acid and xanthine oxidase in heart failure — Emerging data and therapeutic implications
Doehner, W., Jankowska, E. A., Springer, J., Lainščak, M., & Anker, S. D. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.089 · Cited by 88
Changes in Uric Acid Levels and Allopurinol Use in Chronic Heart Failure: Association With Improved Survival
Gotsman, I., Keren, A., Lotan, C., & Zwas, D. R. (2012) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2012.06.528 · Cited by 86
Hypertrophic Cardiomyopathy: A Vicious Cycle Triggered by Sarcomere Mutations and Secondary Disease Hits
Wijnker, P. J. M., Sequeira, V., Kuster, D. W. D., & van der Velden, J. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7236 · Cited by 88
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial
Fitchett, D., Inzucchi, S. E., Zinman, B., Wanner, C., Schumacher, M., Schmoor, C., Ohneberg, K., Ofstad, A. P., Salsali, A., George, J. T., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13615 · Cited by 85
Gout. Novel therapies for treatment of gout and hyperuricemia
Terkeltaub, R. A. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2738 · Cited by 90
Design and Rationale of the PROTECT Study: A Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
Davison, B. A., Cotter, G., Dittrich, H. C., DeLucca, P. T., Mansoor, G. A., Bloomfield, D. M., Ponikowski, P. P., O’Connor, C. M., Metra, M., & Massie, B. M. (2009) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.10.025 · Cited by 83
Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk
Borghi, C., Tykarski, A., Widecka, K., Filipiak, K. J., Domienik‐Karłowicz, J., Kostka-Jeziorny, K., Varga, A., Jaguszewski, M. J., Narkiewicz, K., & Mancia, G. (2018) · Cardiology Journal · doi:10.5603/cj.2018.0116 · Cited by 84
Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure
Otaki, Y., Watanabe, T., Kinoshita, D., Yokoyama, M., Takahashi, T., Toshima, T., Sugai, T., Murase, T., Nakamura, T., Nishiyama, S., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.077 · Cited by 81
Reactive Oxygen Species Induced Pathways in Heart Failure Pathogenesis and Potential Therapeutic Strategies
Mongirdienė, A., Skrodenis, L., Varoneckaitė, L., Mierkytė, G., & Gerulis, J. (2022) · Biomedicines · doi:10.3390/biomedicines10030602 · Cited by 86
Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure
Packer, M. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.030 · Cited by 80
Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan Trial)
Vaduganathan, M., Greene, S. J., Ambrosy, A. P., Mentz, R. J., Subacius, H. P., Chioncel, O., Maggioni, A. P., Swedberg, K. B., Zannad, F. M., Konstam, M. A., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.09.008 · Cited by 79
Self-citation
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
McDowell, K., Welsh, P. I., Docherty, K. F., Morrow, D. A., Jhund, P. S., de Boer, R. A., O’Meara, E., Inzucchi, S. E., Køber, L., Kosiborod, M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2433 · Cited by 83
Uric Acid and Cardiovascular Risk
Leow, M. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmc082360 · Cited by 79
Allopurinol as a Cardiovascular Drug
Kelkar, A. A., Kuo, A., & Frishman, W. H. (2011) · Cardiology in Review · doi:10.1097/crd.0b013e318229a908 · Cited by 77
Effect of Urate-Lowering Therapy on Cardiovascular and Kidney Outcomes
Chen, Q., Wang, Z., Zhou, J., Chen, Z., Li, Y., Li, S., Zhao, H., Badve, S. V., & Lv, J. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05190420 · Cited by 75

Authors: Hare, J. M., Mangal, B., Brown, J., Fisher, C., Freudenberger, R., Colucci, W. S., Mann, D. L., Liu, P., Givertz, M. M., & Schwarz, R. P.
Affiliations: University of Miami (US)
Cardiome (Canada) (CA)
Rutgers, The State University of New Jersey (US)
Boston University (US)
Toronto General Hospital (CA)
Brigham and Women's Hospital (US)
Corresponding author: Hare, Joshua M.
ORCID: Hare, Joshua M.
Brown, Joanne
Colucci, Wilson S.
Mann, Douglas L.
Liu, Peter
Givertz, Michael M.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2008-06
Volume: 51
Issue: 24
Pages: 2301-2309
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2008.01.068
OpenAlex: W1414418298
Cited by: 392
References: 25
Citations by year: 2026: 7 · 2025: 7 · 2024: 18 · 2023: 21 · 2022: 21 · 2021: 18 · 2020: 34 · 2019: 33 · 2018: 20 · 2017: 8 · 2016: 23 · 2015: 16 · 2014: 26 · 2013: 18 · 2012: 41
FWCI: 21.17
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1871 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords: oxypurinol, xanthine oxidase inhibition, heart failure, systolic dysfunction, serum uric acid, hyperuricemia, biomarkers, quality of life
MeSH terms: Adolescent, Adult, Aged, Aged, 80 and over, Double-Blind Method, Enzyme Inhibitors, Female, Health Status Indicators, Heart Failure, Humans, Male, Middle Aged, Oxypurinol, Quality of Life, Surveys and Questionnaires, Systole, Uric Acid, Xanthine Oxidase, Natriuretic Peptide, Brain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Impact of Oxypurinol in Patients With Symptomatic Heart Failure

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks